Hybrid Molecule Enhances Weight Loss and Blood Sugar Control in Mice

Scientists at Helmholtz Munich have engineered a hybrid drug that enhances metabolic activity within cells, demonstrating significant weight loss and improved blood-glucose control in mice. The research, led by Prof. Timo D. Müller, introduces a molecule that leverages the GLP-1/GIP signaling pathway to deliver an additional metabolic agent directly into targeted cells.

The study, published in the journal Nature, details how this novel compound reduces food consumption and promotes greater weight loss compared to current therapies. The approach builds on existing incretin-based treatments, which mimic natural signals regulating satiety and blood sugar levels, but aims to increase their effectiveness.

Mechanism of the Hybrid Drug

Current incretin therapies have transformed management of obesity and type 2 diabetes by activating GLP-1 and GIP receptors. However, improving insulin sensitivity through additional drugs often results in widespread distribution and side effects. To overcome this, the research team created a hybrid molecule combining an incretin-based compound with lanifibranor, a pan-PPAR agonist.

This hybrid attaches to GLP-1 or GIP receptors on cell surfaces, facilitating cellular entry. Inside the cell, lanifibranor activates PPARs, which regulate fat and sugar metabolism at the genetic level. This targeted delivery confines the metabolic effects to cells expressing GLP-1R and GIPR, avoiding systemic exposure.

Simultaneous Activation of Multiple Targets

The compound simultaneously engages five drug targets: two receptors on the cell surface (GLP-1R and GIPR) and three PPAR switches within the cell nucleus. Prof. Müller likens the process to a “Trojan horse,” where the incretin component gains cell entry and the metabolic “cargo” activates only after internalization.

He highlights the advantage of administering the second component at a much lower dose since it travels with the incretin part, potentially reducing side effects associated with systemic administration.

Experimental Results in Mice

In mice with diet-induced obesity, the hybrid therapy led to decreased food intake and more pronounced weight loss than treatment with a GLP-1/GIP co-agonist lacking the metabolic cargo. Dr. Daniela Liskiewicz, co-first author, notes that in direct comparisons, the hybrid’s effects sometimes exceeded those of GLP-1-only drugs.

The data suggest the hybrid not only adds a metabolic mechanism but also amplifies incretin activity itself in animal models.

Metabolic Health Benefits Beyond Weight Loss

The treatment improved blood-glucose regulation and enhanced insulin function, facilitating glucose uptake into tissues while reducing hepatic glucose release. Gastrointestinal side effects were comparable to existing incretin therapies, and no signs of fluid retention or anemia were observed, which are concerns linked to the added drug component.

Future Directions and Human Application

Although the mouse studies indicated potential benefits for heart and liver health, the researchers caution that these findings remain preclinical. Differences in GIP receptor function between mice and humans necessitate further investigation. Prof. Müller states the next step is to optimize the therapy for human use and advance it toward clinical trials, requiring collaboration with industry partners.